Vicki L. Traina-Dorge, Ph.D.
B.S., Biology, Jacksonville State University, Jacksonville, AL
M.T. (ASCP), Medical Technology, Caraway Methodist Medical Center, Birmingham, AL
Ph.D., Microbiology and Immunology, Tulane University Medical Center, New Orleans, LA
- Varicella Virus Infection, Latency, and Reactivation
- Varicella based AIDS Vaccine
- Papillomavirus Infection and Progression to Cervical Cancer
- Respiratory Syncytial Virus Infection and Pathogenesis
Dr. Traina-Dorge is an Associate Professor of Microbiology and Immunology at the Tulane University School of Medicine and a Molecular Virologist within the Division of Microbiology at the Tulane National Primate Research Center (TNPRC), Covington, Louisiana. She has a broad background in virology, immunology, and pathogenesis of nonhuman primates (NHP). This includes over twenty years’ experience developing NHP models of pathogenic viral infections that include agents: simian immunodeficiency virus (SIV), simian T cell lymphotropic virus (STLV), simian varicella virus (SVV), respiratory syncytial virus (RSV), rhesus papillomavirus (RhPV), mouse mammary tumor virus (MMTV), and alphaviruses: Eastern and Western equine encephalitis viruses (EEE and WEE) to study of molecular mechanisms of viral pathogenesis, carcinogenesis, molecular epidemiology, and vaccine development. Following development of a NHP model of shingles/zoster, her lab is currently working to identify cell types and cell signaling molecules for SVV trafficking in virus reactivation and onset of shingles. They are developing and testing a live attenuated recombinant SVV-SIV vaccine for both protective and therapeutic treatments against SIV challenge in the NHP, with ultimate development towards a vaccine against HIV. They are also developing a NHP cervical cancer model with RhPV, having demonstrated genital infection with RhPV that produces precancerous lesions, with increased frequency upon immunosuppression and co-infection with SIV, similar to that seen in AIDS patients. Finally, her laboratory is studying the protective efficacy of a virus-like-particle (VLP) vaccines against pathogenic alphaviruses (EEE and WEE).
The TNPRC is a division of Tulane University (985) 871-6201 email@example.com